Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Amyloid Fibrils03:03

Amyloid Fibrils

11.6K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.6K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

822
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
822

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TAF15 amyloids propagate via defined motifs in a prion-like fashion.

Nature communications·2026
Same author

Expansion microscopy of banked brain tissue.

Free neuropathology·2026
Same author

Lewy pathology largely absent in prefrontal cortices of Parkinson's disease patients undergoing deep brain stimulation.

NPJ Parkinson's disease·2026
Same author

Emerging directions in tauopathy research.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Validity of the NINDS traumatic encephalopathy syndrome criteria for predicting chronic traumatic encephalopathy.

medRxiv : the preprint server for health sciences·2026
Same author

A new AI assisted approach aligns data standards and accelerates interoperability in biomedical research.

NPJ digital medicine·2026

Related Experiment Video

Updated: Jan 15, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.9K

Primary age-related tauopathy.

Timothy E Richardson1,2, Jamie M Walker3,4,5,6,7, Kurt Farrell3,4,6,8

  • 1Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, Icahn Building, 9.20E, 1468 Madison Avenue, New York, NY, 10029, USA. timothy.richardson@mountsinai.org.

Acta Neuropathologica
|October 9, 2025
PubMed
Summary

Primary age-related tauopathy (PART) is a key concept for understanding brain aging and neurodegeneration. This review examines PART

Keywords:
AgingAlzheimer’s disease neuropathologic change (ADNC)CA1 hippocampal subfieldCognitive reserveCornu ammonis 2 (CA2) hippocampal subfieldLimbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC)Primary age-related tauopathy (PART)Resilience

More Related Videos

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells
12:55

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells

Published on: October 10, 2017

9.4K
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

8.9K

Related Experiment Videos

Last Updated: Jan 15, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.9K
Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells
12:55

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells

Published on: October 10, 2017

9.4K
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

8.9K

Area of Science:

  • Neuropathology
  • Neurodegenerative Diseases
  • Aging Research

Background:

  • Primary age-related tauopathy (PART) was defined in 2014 to describe tau pathology without significant amyloid.
  • PART aids in interpreting biomarker profiles and differentiating aging-related tau from Alzheimer's disease.
  • Over a decade, PART has become crucial for understanding early-stage tauopathy in aging populations.

Purpose of the Study:

  • To critically evaluate the neuropathological features, clinical correlates, and molecular basis of PART ten years after its inception.
  • To synthesize recent advances in neuroimaging, biomarkers, genetics, and epidemiology related to PART.
  • To propose revisions to the original PART criteria and identify future research priorities.

Main Methods:

  • Comprehensive literature review synthesizing recent findings in PART research.
  • Analysis of neuroimaging, biomarker, genetic, and epidemiological data.
  • Critical evaluation of existing neuropathological and clinical data.

Main Results:

  • PART has been widely adopted, improving the understanding of tau pathology in aging.
  • Significant advances have been made in neuroimaging and biomarker detection for PART.
  • Key questions persist regarding PART's pathogenesis, clinical significance, and relationship to other tauopathies.

Conclusions:

  • PART serves as a valuable framework but requires refinement of its criteria.
  • Further research is needed to clarify whether PART is a distinct disease or a universal aging feature.
  • Defining precise mechanisms, biomarkers, and clinical criteria for PART is a priority.